Countdown begins for 3rd generation lung cancer drugs among Hanmi, BI and AZ
Competed by Hanmi Pharm, Boehringer Ingelheim and AstraZeneca, launches of the 3rd generation non-small cell lung cancer treatments have begun a countdown.
According to the Ministry of Food and Drug Safety(MFDS) and a person concerned to Hanmi Pharm on the 24th, the Hanmi Pharm’s 3rd generation...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
